NIH Hits Pause on SBIR and STTR: What the Latest Guidance Means for Your Funding Strategy
NIH abruptly paused SBIR and STTR activity, creating uncertainty for applicants who now require strategy, preparation, and airtight compliance more than ever.
NIH abruptly paused SBIR and STTR activity, creating uncertainty for applicants who now require strategy, preparation, and airtight compliance more than ever.
Assembling a team with the right blend of expertise, leadership, and collaborative partnerships can significantly strengthen your proposal.
For startups pursuing non-dilutive funding, the SBIR/STTR programs offer a critical pathway to advance research and development while preserving ownership.
While federal programs like SBIR and STTR often get the spotlight, state-level non-dilutive funding opportunities can be equally valuable for startups seeking financial support for research, development, and growth.
Customer discovery plays a pivotal role in crafting a credible and compelling SBIR/STTR application, especially when it comes to strengthening your commercialization plan.
A critical factor in crafting a successful SBIR/STTR application is ensuring that your proposal aligns with the specific priorities and goals of the funding agency.
Turning an innovative idea into a well-structured research plan is one of the most critical steps in preparing a successful SBIR/STTR application.
Navigating the SBIR/STTR application process can be complex, especially for small businesses that are new to federal funding. Between writing a compelling technical narrative, crafting a detailed budget, and ensuring compliance with federal guidelines, the process requires a significant investment of time and expertise.
Securing non-dilutive funding can be a transformative opportunity for startups, providing the financial support needed to develop and commercialize innovative solutions without giving up equity.
For startups advancing to Phase II and beyond in the SBIR/STTR program, the cost match requirement can be a pivotal consideration.